911爆料网

Haematology - Acute Leukaemia & MDS

A LIST OF OUR EARLY PHASE haematology (Acute Leukaemia & MDS)听TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALS

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the听hyperlinked听Local Project Reference (LRP)听ID, which will take you to the UCLH Find a Study database.

听

75276617ALE1002 - Menin Combo A Phase 1b Study of JNJ-75276617 in Combination with AML-Directed Therapies:听 A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
Local Project Reference:
Principal Investigator:	Dr Jenny O'Nions
Drug Class/ Treatrment:	JNJ-75276617 (Menin-KMT2A Inhibitor)
Patient Population:	Acute Myeloid Leukemia (AML) with KMT2A or NPM1 Alterations
Trial Hosted By -听NIHR UCLH Clinical Research Facility (CRF)

EP0042-101 A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate theSafety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies.
Local Project Reference:
Principal Investigator:	Dr Jenny O'Nions
Drug Class/ Treatrment:	FLT3 inhibitor & Aurora Kinase Inhibitor: EP0042 Monotherapy and Combination - Oral administration
Patient Population:	Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndromes (MDS)
Trial Hosted By -听NIHR UCLH Clinical Research Facility (CRF)

PROMISE Investigation into the combination of PLX2853 with Ruxolitinib in patients with intermediate-2 or high risk myelofibrosis not receiving an adequate response with ruxolitinib alone.
Local Project Reference:
Principal Investigator:	Dr. Jenny O'Nion
Drug Class/ Treatrment:	PLX2853 (BET Inhibitor) + Ruxolitinib (JAK Inhibitor)
Patient Population:	Intermediate or High-Risk Myelofibrosis
Trial Hosted By -听NIHR UCLH Clinical Research Facility (CRF)

CL1-65487-003 Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multicentre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl2 inhibitor combined with azacitidine in adult patients with previously untreated acute myeloid leukemia not eligible for intensive treatment
Local Project Reference:
Principal Investigator:	Dr Jenny O'Nions
Drug Class/ Treatrment:	S65487 (BCL2 Inhibitor) Combination S65487 and Azacitidine.听Receiving 7 days Azacitidne and weekly S65487 infusions through the vein every 28 days.
Patient Population:	Acute Myeloid Leukaemia (AML)
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

听

FEDORA FEDORA : 听A phase II study to evaluate the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis
Local Project Reference:
Principal Investigator:	Dr Donal McLornan
Drug Class/ Treatrment:	Fedratanib听(JAK2 Inhibitor) + Ropeginterferon Alfa-2b (Pegylated Interferon)
Patient Population:	Myelofibrosis
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

ELECTRA A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Local Project Reference:
Principal Investigator:	Dr Satyen Gohil
Drug Class/ Treatrment:	ELA026听(IgG1 SIRP-Directed Monoclonal Antibody)
Patient Population:	Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Adults and Adolescents (鈮�12 years at the time of HLH diagnosis)
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

KCAT19 KCAT19: Allogeneic T cells expressing T cell receptor-KDEL and the chimeric antigen receptor CAT19 for the treatment of advanced CD19+ malignancies
Local Project Reference:	126800
Principal Investigator:	Dr Maeve O鈥橰eilly
Drug Class/ Treatrment:	CAR T-Cell Therapy
Patient Population:	Advanced CD19+ Malignancies
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

听

Principal Investigator(s)

Dr. jenny o'nions

Consultant Haematologist